Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Now Covered by StockNews.com

Posted by on Jul 31st, 2023

Equities researchers at StockNews.com initiated coverage on shares of Ampio Pharmaceuticals (NYSEAMERICAN:AMPE – Get Free Report) in a research report issued on Saturday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Ampio Pharmaceuticals Stock Performance

Shares of AMPE opened at $0.24 on Friday. The stock has a 50-day simple moving average of $0.26 and a 200-day simple moving average of $0.26. Ampio Pharmaceuticals has a 1 year low of $0.18 and a 1 year high of $2.39. The stock has a market capitalization of $3.56 million, a PE ratio of -0.19 and a beta of 1.72.

Ampio Pharmaceuticals (NYSEAMERICAN:AMPE – Get Free Report) last announced its quarterly earnings data on Monday, May 8th. The specialty pharmaceutical company reported ($0.26) earnings per share for the quarter.

Institutional Trading of Ampio Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of AMPE. HRT Financial LP boosted its position in shares of Ampio Pharmaceuticals by 1,399.2% in the first quarter. HRT Financial LP now owns 217,052 shares of the specialty pharmaceutical company’s stock worth $50,000 after buying an additional 202,574 shares during the period. Two Sigma Advisers LP lifted its holdings in shares of Ampio Pharmaceuticals by 304.3% in the 3rd quarter. Two Sigma Advisers LP now owns 432,216 shares of the specialty pharmaceutical company’s stock worth $26,000 after purchasing an additional 325,300 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Ampio Pharmaceuticals by 20.0% during the third quarter. Vanguard Group Inc. now owns 9,954,092 shares of the specialty pharmaceutical company’s stock worth $602,000 after acquiring an additional 1,662,127 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Ampio Pharmaceuticals by 73.5% in the second quarter. Price T Rowe Associates Inc. MD now owns 394,100 shares of the specialty pharmaceutical company’s stock valued at $66,000 after purchasing an additional 166,979 shares during the period. Finally, Millennium Management LLC raised its stake in Ampio Pharmaceuticals by 998.6% during the 2nd quarter. Millennium Management LLC now owns 2,035,413 shares of the specialty pharmaceutical company’s stock valued at $342,000 after acquiring an additional 1,850,138 shares in the last quarter. Hedge funds and other institutional investors own 3.44% of the company’s stock.

About Ampio Pharmaceuticals

(Get Free Report)

Ampio Pharmaceuticals, Inc, a biopharmaceutical company, develops therapies for the treatment of osteoarthritis-related pain. It focuses on the preclinical development of AR-300, a novel proprietary, small molecule formulation for the treatment of osteoarthritis of the knee. The company is headquartered in Englewood, Colorado.

Featured Articles

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.